摘要
目的分析头颈部鳞癌组织多药耐药基因产物Ｐ糖蛋白（Ｐ１７０）的表达及临床意义。方法应用ＪＳＢ－１单克隆抗体。采用免疫组化（ＳＰ）法对３０例头颈部鳞癌（口腔癌１４例，唇癌１０例，皮肤癌６例）患者ｍｄｒ１基因产物Ｐ１７０进行检测。结果Ｐ１７０表达率为６３．３％，其中初诊组患者Ｐ１７０阳性率为４７．４％，复发组患者９０．９％。初诊阳性率明显低于复发组阳性率（Ｐ＜０．０１）。以唇癌Ｐ１７０阳性表达率最低。另外对１０例唇癌病人进行初步观察，Ｐ１７０表达阴性组化疗有效率（ＣＲ＋ＰＲ）９２％，显著高于阳性组４７．６％。结论提示头颈部鳞癌多药耐药与Ｐ１７０表达有关。
Multidrug resistance (MDR) remain a major obstacle to successful treatment of cancer.The mechanism of MDR involves multiple factors among which P-gp is generally considered to play an important role in MDR.The present study investigated the P-gp expression,a product of mdr1 gene,in 30 patients with squamous carcinoma on the head and neck (14 patients with carcinoma of the oral cavity,10 patients with carcinama of the lip and 6 patients with carcinoma of the skin).by immunocytochemistry using monoclonal antibody JSB-1 against human P-gp.The results showed that the positive rate of P-gp expression was 63.3% with 47.4% in newly diagnosed patients and 90.9% in relapsed patients respectively.The positive rate in newly diagnosed patients was significantly lower than that in relapsed patients (P< 0.01 ).The positive rate in patients with carcinoma of the lip was lowest than that than that in patients with carcinoma of the oral cavity and the skin.In addition,preliminary observation 10 patients with carcinoma of the lip patients negative for P-gp expression had a higher remission rate (CR+PR) 92% as compared to patients positive for P-gp. only 47.6% . These results suggest that MDR in patients with Squamous carcinoma on the head and neck correlate with the expression of P-gp.
出处
《中国肿瘤临床与康复》
1999年第3期27-28,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
